Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer

Barbara A. Jereczek-Fossa, Laura Fariselli, Giancarlo Beltramo, Gianpiero Catalano, Flavia Serafini, Cristina Garibaldi, Raffaella Cambria, Lorenzo Brait, Marco Possanzini, Livia C. Bianchi, Andrea Vavassori, Dario Zerini, Franco Orsi, Ottavio de Cobelli, Roberto Orecchia

Research output: Contribution to journalArticlepeer-review

Abstract

We report on 14 patients treated with linac- or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrence from prostate cancer, up to the mean dose of 30 Gy/3 fractions. At the mean follow-up of 18.6 months, five patients experienced clinical out-field progression. Toxicity was minimal. Further investigation is warranted in order to identify the patients that benefit most from this treatment modality and to define the optimal association of such local approach with androgen deprivation. Hopefully, effective local therapy might reduce the burden of systemic therapies given to the recurrent/metastatic prostate cancer patients.

Original languageEnglish
Pages (from-to)14-17
Number of pages4
JournalRadiotherapy and Oncology
Volume93
Issue number1
DOIs
Publication statusPublished - Oct 2009

Keywords

  • Lymph node recurrence
  • Recurrent prostate cancer
  • Robotic stereotactic radiotherapy
  • Stereotactic radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology

Fingerprint Dive into the research topics of 'Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer'. Together they form a unique fingerprint.

Cite this